Vivos Therapeutics (NASDAQ:VVOS) Stock Price Down 6.7% – Here’s What Happened

Shares of Vivos Therapeutics, Inc. (NASDAQ:VVOS) traded down 6.7% during trading on Monday . The stock traded as low as $1.51 and last traded at $1.52. 50,965 shares traded hands during mid-day trading, a decline of 52% from the average session volume of 106,025 shares. The stock had previously closed at $1.63.

Analysts Set New Price Targets

A number of analysts have issued reports on VVOS shares. HC Wainwright began coverage on Vivos Therapeutics in a research note on Monday, November 17th. They issued a “buy” rating and a $7.00 price target on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Vivos Therapeutics in a research report on Wednesday, January 21st. Zacks Research raised shares of Vivos Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, December 1st. Finally, Ascendiant Capital Markets dropped their price objective on Vivos Therapeutics from $6.50 to $5.50 and set a “buy” rating for the company in a report on Wednesday, December 3rd. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $4.92.

Vivos Therapeutics Trading Down 6.7%

The company has a quick ratio of 0.78, a current ratio of 0.78 and a debt-to-equity ratio of 3.31. The firm has a market cap of $15.91 million, a P/E ratio of -0.86 and a beta of 6.93. The business’s 50 day moving average is $1.88 and its 200-day moving average is $2.70.

Hedge Funds Weigh In On Vivos Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in VVOS. Acorn Wealth Advisors LLC bought a new stake in shares of Vivos Therapeutics during the 4th quarter worth about $30,000. XTX Topco Ltd purchased a new stake in shares of Vivos Therapeutics in the second quarter worth approximately $65,000. B. Riley Wealth Advisors Inc. acquired a new stake in shares of Vivos Therapeutics during the second quarter worth approximately $220,000. DRW Securities LLC boosted its holdings in shares of Vivos Therapeutics by 179.5% during the fourth quarter. DRW Securities LLC now owns 115,907 shares of the company’s stock worth $235,000 after purchasing an additional 74,441 shares during the period. Finally, Connective Capital Management LLC purchased a new position in Vivos Therapeutics during the third quarter valued at approximately $620,000. 26.35% of the stock is currently owned by institutional investors and hedge funds.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.